Skip to main content

Clinical Pipeline

UCB is committed to developing novel treatments to address the unmet needs of patients living with chronic autoimmune & inflammatory conditions as well as rare diseases. Our promising pipeline of antibody-based and small molecule agents are being rigorously evaluated in multiple ongoing clinical trials. These agents and their uses are investigational and have not been approved by the U.S. Food and Drug Administration.

Immunology Late-Stage Pipeline
Immunology Late-Stage Pipeline
Rare Disease Late-Stage Pipeline
rare_disease

The information provided here represents molecules that are currently under clinical investigation and are not approved by the U.S. Food and Drug Administration.

For more information on UCB’s full pipeline of products under clinical development, visit UCB R&D pipeline.